Analyst Ratings February 23, 2026

UBS Lifts Bath & Body Works Price Target After Softer-Than-Expected Sales Pressure

Firm raises target to $22, sees modest EPS upside for Q4 and expects fiscal 2026 guidance to bracket Street estimates

By Leila Farooq BBWI
UBS Lifts Bath & Body Works Price Target After Softer-Than-Expected Sales Pressure
BBWI

UBS increased its price target on Bath & Body Works Inc. (BBWI) to $22.00 from $21.00 while keeping a Neutral rating after channel checks showed sales trends were slightly less pressured than anticipated. The bank predicts a small 5-cent Q4 fiscal 2025 EPS beat and expects the company's fiscal 2026 guidance of $2.30 to $2.65 to encompass the Street's $2.57 estimate. UBS also notes a roughly balanced risk profile into the earnings event and anticipates lower volatility than the options market currently prices.

Key Points

  • UBS raised its price target on Bath & Body Works to $22.00 from $21.00 and maintained a Neutral rating after channel checks indicated sales were slightly less pressured than expected.
  • UBS expects a small 5-cent Q4 fiscal 2025 EPS beat and anticipates fiscal 2026 EPS guidance of $2.30 to $2.65, which brackets the Street consensus of $2.57.
  • Bath & Body Works launched an official U.S. storefront on a major online marketplace and declared a regular quarterly dividend of $0.20 per share payable March 6, 2026.

UBS raised its price target on Bath & Body Works Inc. (NYSE:BBWI) to $22.00 from $21.00 while retaining a Neutral rating on the stock. The firm said its channel checks indicate sales trends at the specialty retailer have been slightly less pressured than the firm had expected, supporting the case for a small upside to near-term earnings.

Specifically, UBS projects the company can deliver a modest 5-cent beat to fourth-quarter fiscal 2025 adjusted earnings per share. The bank anticipates Bath & Body Works will provide fiscal 2026 EPS guidance in a range between $2.30 and $2.65 - a band that brackets the consensus Street forecast of $2.57. UBS characterized such guidance as likely to align with market expectations and said it does not expect the report to materially change sentiment toward the stock.

On the risk and volatility front, UBS described the upside and downside around the upcoming earnings release as balanced. The options market is currently implying a move of plus or minus 10.7% around the event, compared with a 7.7% historical average move for the company. UBS expressed an expectation for less volatility than the options-implied plus or minus 10.7% range.

Separately, Bath & Body Works has expanded its direct-to-consumer footprint by launching an official storefront on a major U.S. online marketplace. The company is offering a range of body care and home fragrance products through the storefront, including popular scent variants such as Champagne Toast and Eucalyptus Spearmint, alongside items like fine fragrance mists and candles.

In shareholder returns news, the company declared a regular quarterly dividend of $0.20 per share. The dividend is payable on March 6, 2026 to holders of record as of February 20, 2026.

The analyst landscape shows several recent moves. Jefferies has initiated coverage with a Hold rating and a $24.00 price target, citing strong foot and web traffic as reasons for raising its fourth-quarter estimates. A separate UBS note reiterated a Neutral rating with a $17.00 price target and forecasted a -1% five-year EPS compound annual growth rate as the company undergoes a multi-year business revamp. Meanwhile, BofA Securities trimmed its price target to $26.00 from $32.00 but maintained a Buy rating following third-quarter results that fell short of expectations.

Taken together, the analyst actions and the company's new e-commerce distribution channel and dividend decision underline ongoing strategic adjustments at Bath & Body Works. UBS's latest adjustment to its price target and its expectation for modest EPS outperformance suggest the bank views near-term operational trends as mildly supportive, even as broader sentiment appears unlikely to shift markedly on the upcoming report.

Risks

  • Earnings volatility around the upcoming report - options markets imply a plus or minus 10.7% move, higher than the 7.7% historical average, indicating potential for larger-than-normal share swings that could affect equity and derivatives traders.
  • Analyst divergence and ongoing business revamp - differing price targets and forecasts, including a UBS projection of a -1% five-year EPS CAGR, highlight execution uncertainty for investors in consumer discretionary and retail sectors.
  • Mixed recent results - BofA lowered its price target after third-quarter results missed expectations, underscoring the risk that future quarterly performance could disappoint and impact investor sentiment in the retail and consumer-products markets.

More from Analyst Ratings

Jefferies Increases Chemours Price Target to $17 Citing Opteon Support; Firm Keeps Hold Rating Feb 23, 2026 Jefferies Lifts Lithium Americas Price Target to $8, Cites Production Ramp and Offtake Visibility Feb 23, 2026 Brookline Capital Lifts C4 Therapeutics Price Target to $30 as Cemsidomide Trials Advance Feb 23, 2026 Jefferies Lifts Fisher & Paykel Healthcare Target After Company Tightens Fiscal 2026 Guidance Feb 23, 2026 William Blair Sticks With Outperform on JFrog as Analysts Weigh Security Positioning Feb 23, 2026